Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects

Clinical and Experimental Medicine

Volumn 7, Issue 4, 2007, Pages 188-190

  Nakamura, K ^a,b   Yamagishi, S I ^b   Matsui, T ^b   Adachi, H ^b   Takeuchi, M ^c   Imaizumi, T ^b  

^a Nakamura Clinic   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HYPERLIPIDEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; VASCULAR DISEASE;

AGED; DIABETES MELLITUS, TYPE 2; DIASTOLE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC;

EID: 38149001527     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-007-0146-7     Document Type: Letter

References (11)

1. Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299
2. Park L, Raman KG, Lee KJ et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4:1025-1031
3. Enomoto M, Adachi H, Yamagishi S et al (2006) Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 55:912-917
4. Nakamura K, Yamagishi S, Adachi H et al (2007) Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 3:185-189
5. Humpert PM, Djuric Z, Kopf S et al (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovascular Diabetology 6:9
6. Steiner M, Reinhardt KM, Krammer B et al (1994) Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 72:979-984
7. Nakamura K, Yamagishi S, Nakamura Y et al (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70:137-141
8. Pachydaki SI, Tari SR, Lee SE et al (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807-815
9. Miura J, Yamamoto Y, Osawa M et al (2007) Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 27:253-254
10. Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587-2593
11. Kass DA, Shapiro EP, Kawaguchi M et al (2001) Improved arterial compliance by a novel advanced glycation endproduct crosslink breaker. Circulation 104:1464-1470